Page last updated: 2024-10-27

fentanyl and Neuralgia

fentanyl has been researched along with Neuralgia in 35 studies

Fentanyl: A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078)
fentanyl : A monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid.

Neuralgia: Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.

Research Excerpts

ExcerptRelevanceReference
" We evaluated the efficacy of sublingual fentanyl tablet (SLF) for the treatment of BTP in opioid-tolerant patients with chronic musculoskeletal pain with neuropathic component in terms of relief of pain intensity and assessed whether hypothetical pain relief impacts on quality of life (QoL)."9.20Efficacy and safety of sublingual fentanyl tablets for the management of breakthrough pain in patients with chronic musculoskeletal pain with neuropathic component: multicenter prospective study. ( Camba-Rodríguez, A; Cánovas-Martínez, L; Carceller-Ruiz, JJ; De la Iglesia-López, A; Díaz-Parada, P; Domínguez-Suárez, E; Freire-Vila, E; Iglesias, BG; Illodo-Miramontes, G; López-Ulloa, B, 2015)
" IV fentanyl PCA was used for pain control in 16 patients with lower extremity, neuropathic/ischaemic pain, scheduled for major lower extremity amputation."7.76Case report. Intravenous fentanyl patient-controlled analgesia for perioperative treatment of neuropathic/ischaemic pain in haemodialysis patients: a case series. ( Aretha, D; Filos, KS; Karanikolas, M; Kiekkas, P; Monantera, G; Tsolakis, I, 2010)
" Pain intensity (PI) (rated on an 11-point pain scale, from 0 = no pain to 10 = worst pain) and other outcomes were assessed before dosing and for 2 hours after dosing."6.73Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study. ( Hale, M; Messina, J; Simpson, DM; Xie, F, 2007)
"A number of studies have been published proposing various approaches to the treatment of neuropathic pain; however, to our knowledge, no attempts have been made to compare gabapentin and fentanyl in patients with lumbar radiculopathy."5.30Gabapentin versus Transdermal Fentanyl Matrix for the Alleviation of Chronic Neuropathic Pain of Radicular Origin: A Randomized Blind Multicentered Parallel-Group Noninferiority Trial. ( Hwang, CJ; Kim, JH; Lee, JH; Min, SH; Park, KW; Seo, HY; Song, KS, 2019)
" We evaluated the efficacy of sublingual fentanyl tablet (SLF) for the treatment of BTP in opioid-tolerant patients with chronic musculoskeletal pain with neuropathic component in terms of relief of pain intensity and assessed whether hypothetical pain relief impacts on quality of life (QoL)."5.20Efficacy and safety of sublingual fentanyl tablets for the management of breakthrough pain in patients with chronic musculoskeletal pain with neuropathic component: multicenter prospective study. ( Camba-Rodríguez, A; Cánovas-Martínez, L; Carceller-Ruiz, JJ; De la Iglesia-López, A; Díaz-Parada, P; Domínguez-Suárez, E; Freire-Vila, E; Iglesias, BG; Illodo-Miramontes, G; López-Ulloa, B, 2015)
"Fentanyl, a short-acting synthetic pure opiate, offers an excellent option for the treatment of cancer and chronic pain."4.86Intranasal fentanyl: from pharmacokinetics and bioavailability to current treatment applications. ( Mystakidou, K; Panagiotou, I, 2010)
" IV fentanyl PCA was used for pain control in 16 patients with lower extremity, neuropathic/ischaemic pain, scheduled for major lower extremity amputation."3.76Case report. Intravenous fentanyl patient-controlled analgesia for perioperative treatment of neuropathic/ischaemic pain in haemodialysis patients: a case series. ( Aretha, D; Filos, KS; Karanikolas, M; Kiekkas, P; Monantera, G; Tsolakis, I, 2010)
"Cancer pain is still inadequately treated in up to 60% of cancer patients."2.82Methadone is superior to fentanyl in treating neuropathic pain in patients with head-and-neck cancer. ( Geurts, JW; Haumann, J; Joosten, EA; Kremer, B; van den Beuken-van Everdingen, MH; van Kuijk, SM, 2016)
" Pain intensity (PI) (rated on an 11-point pain scale, from 0 = no pain to 10 = worst pain) and other outcomes were assessed before dosing and for 2 hours after dosing."2.73Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study. ( Hale, M; Messina, J; Simpson, DM; Xie, F, 2007)
"Forty-eight patients with noncancer neuropathic pain who had participated in a randomized controlled trial with intravenous fentanyl (FENiv) infusions received prolonged transdermal fentanyl (FENtd) in an open prospective study."2.69Prolonged treatment with transdermal fentanyl in neuropathic pain. ( Dellemijn, PL; van Duijn, H; Vanneste, JA, 1998)
"Lidocaine 50 mg was associated with a greater decrease in systolic blood pressure and a greater need for ephedrine."2.69A comparison of minidose lidocaine-fentanyl and conventional-dose lidocaine spinal anesthesia. ( Ben-David, B; DeMeo, PJ; Frankel, R; Gurevitch, A; Lucyk, C; Maryanovsky, M; Solosko, D; Volpin, G, 2000)
" Furthermore, enduring exacerbation of nociceptive hypersensitivity is also observed when the same dosing regimen for either morphine, fentanyl, or oxycodone begins 1 month after nerve injury."1.51Oxycodone, fentanyl, and morphine amplify established neuropathic pain in male rats. ( Ball, JB; Fabisiak, T; Grace, PM; Green-Fulgham, SM; Kwilasz, AJ; Maier, SF; Watkins, LR, 2019)
"Buprenorphine is a frequently used opioid in the treatment of neuropathic pain component that is often present in patients with cancer."1.40A successful switch from transdermal fentanyl to transdermal buprenorphine in a patient with neuropathic pain: a case report. ( Leppert, W, 2014)
"Both buprenorphine and fentanyl were well tolerated."1.39Safety and efficacy of transdermal buprenorphine and transdermal fentanyl in the treatment of neuropathic pain in AIDS patients. ( Cannata, F; Canneti, A; Di Marco, P; Luzi, M; Pasqualitto, F; Reale, C; Spinoglio, A, 2013)
"Additionally, gabapentin was given for neuropathic pain uncontrolled by opioids."1.37[Oxycodone and pregabalin using transdermal fentanyl patch provided relief of symptoms for postherpetic neuropathic pain in a patient with non-small cell lung cancer]. ( Ando, A; Nishimura, D; Shibahara, H; Suzuki, S; Uematsu, N, 2011)
"Neuropathic pain is associated with several sensory abnormalities, including allodynia as well as spontaneous pain."1.34Opioid self-administration in the nerve-injured rat: relevance of antiallodynic effects to drug consumption and effects of intrathecal analgesics. ( Buechler, NL; Eisenach, JC; Kim, SA; Martin, TJ; Porreca, F, 2007)
"The mechanisms responsible for neuropathic pain are not fully understood."1.33[Transdermal fentanyl for neuropathic pain: a case report]. ( Kara, I; Otelcioğlu, S; Reisli, R; Tuncer, S, 2006)
"Epidural infiltration is a reliable treatment for neuralgia after lumbar sympathectomy."1.27Neuralgia following lumbar sympathectomy. ( Buche, M; Joucken, K; Mayne, A; Randour, P; Schoevaerdts, JC, 1988)

Research

Studies (35)

TimeframeStudies, this research(%)All Research%
pre-19902 (5.71)18.7374
1990's1 (2.86)18.2507
2000's6 (17.14)29.6817
2010's23 (65.71)24.3611
2020's3 (8.57)2.80

Authors

AuthorsStudies
Xiong, J2
Jin, J1
Gao, L1
Hao, C2
Liu, X2
Liu, BF2
Chen, Y2
Zhang, G2
Zhuang, T1
Ma, Y1
Xu, J1
Ye, J1
Ma, R1
Zhang, S1
Takemura, M1
Niki, K1
Okamoto, Y1
Matsuda, Y1
Omae, T1
Takagi, T1
Ueda, M1
Mousa, SA1
Shaqura, M1
Al-Madol, M1
Tafelski, S1
Khalefa, BI1
Shakibaei, M1
Schäfer, M2
Haumann, J3
van Kuijk, SMJ1
Joosten, EA3
van den Beuken-van Everdingen, MHJ1
Bechakra, M1
Moerdijk, F1
van Rosmalen, J1
Koch, BCP1
van der Rijt, CCD1
Sillevis Smitt, PAE1
Jongen, JLM1
Hwang, CJ1
Lee, JH1
Kim, JH1
Min, SH1
Park, KW1
Seo, HY1
Song, KS1
Green-Fulgham, SM1
Ball, JB1
Kwilasz, AJ1
Fabisiak, T1
Maier, SF1
Watkins, LR1
Grace, PM1
Gálvez, R1
Hans, G1
Falke, D1
Steigerwald, I1
Canneti, A1
Luzi, M1
Di Marco, P1
Cannata, F1
Pasqualitto, F1
Spinoglio, A1
Reale, C1
Eroglu, A1
Vardanyan, RS1
Hruby, VJ1
Kanbara, T2
Nakamura, A3
Shibasaki, M2
Mori, T2
Suzuki, T3
Sakaguchi, G2
Kanemasa, T2
Harumiya, M1
Iwase, Y1
Masumoto, A1
Komiya, S1
Cánovas-Martínez, L1
Carceller-Ruiz, JJ1
Díaz-Parada, P1
Illodo-Miramontes, G1
Freire-Vila, E1
De la Iglesia-López, A1
Iglesias, BG1
López-Ulloa, B1
Domínguez-Suárez, E1
Camba-Rodríguez, A1
Doddrell, C1
Tripathi, SS1
Hayek, SM1
Sweet, JA1
Miller, JP1
Sayegh, RR1
Geurts, JW2
van Kuijk, SM2
Kremer, B2
van den Beuken-van Everdingen, MH2
Derry, S1
Stannard, C1
Cole, P1
Wiffen, PJ1
Knaggs, R1
Aldington, D1
Moore, RA1
Ruan, X1
Luo, JJ1
Kaye, AD1
Panagiotou, I1
Mystakidou, K1
Karanikolas, M1
Aretha, D1
Kiekkas, P1
Monantera, G1
Tsolakis, I1
Filos, KS1
Narita, M1
Imai, S1
Ozeki, A1
Asato, M1
Rahmadi, M1
Sudo, Y1
Hojo, M1
Uezono, Y1
Devi, LA1
Kuzumaki, N1
Shibahara, H1
Ando, A1
Suzuki, S1
Uematsu, N1
Nishimura, D1
Leppert, W1
Naja, MZ1
Al-Tannir, MA1
Maaliki, H1
El-Rajab, M1
Ziade, MF1
Zeidan, A1
Martin, TJ1
Kim, SA1
Buechler, NL1
Porreca, F1
Eisenach, JC1
Tuncer, S1
Reisli, R1
Kara, I1
Otelcioğlu, S1
Simpson, DM1
Messina, J1
Xie, F1
Hale, M1
Dellemijn, PL1
van Duijn, H1
Vanneste, JA1
Ben-David, B1
Maryanovsky, M1
Gurevitch, A1
Lucyk, C1
Solosko, D1
Frankel, R1
Volpin, G1
DeMeo, PJ1
Bleeker, CP1
Bremer, RC1
Dongelmans, DA1
van Dongen, RT1
Crul, BJ1
Buche, M1
Randour, P1
Mayne, A1
Joucken, K1
Schoevaerdts, JC1
Fine, PG1
Ashburn, MA1

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Gabapentin Versus Transdermal Fentanyl Matrix (TDF) for Chronic Neuropathic Pain (of Radicular Origin): A Multicenter Randomized, Parallel Group, Rater Blinded, Non-inferiority Trial[NCT01127100]Phase 4108 participants (Actual)Interventional2010-05-31Completed
An Evaluation of the Effectiveness and Tolerability of Tapentadol Hydrochloride Prolonged Release, and Tapentadol Hydrochloride Immediate Release on Demand, in Subjects With Severe Chronic Nociceptive, Mixed or Neuropathic Low Back Pain Taking WHO Step II[NCT00986258]Phase 3136 participants (Actual)Interventional2009-10-30Terminated (stopped due to This clinical trial was terminated early, due to slow recruitment and study drug shortages.)
Methadone for 'Adenocarcinopathic' Pain Treatment: Methadone vs. Morphine Vanguard RCT[NCT05325164]Phase 30 participants (Actual)Interventional2022-09-30Withdrawn (stopped due to Trial not started; change in Sponsor and Principal Investigator, trial to be registered again by new Sponsor/Investigator if it is started.)
A Randomized Trial of Intranasal Fentanyl Versus Placebo as an Adjunct to Lidocaine Infiltration in Adults Undergoing Abscess Incision and Drainage in the Emergency[NCT03872700]Phase 349 participants (Actual)Interventional2019-08-01Completed
A Prospective Study Comparing the Efficacy and Safety of 100 mcg and 200 mcg of Intranasal Fentanyl Pectin Spray as an Analgesic in Adult Males Undergoing Outpatient Cystoscopic Procedures[NCT01756651]Phase 120 participants (Actual)Interventional2013-02-28Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Average Pain Intensity Before the Start of Tapentadol Treatment

"For this pain assessment, the participant was to indicate the level of average pain experienced over the previous 3 days on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated no pain and a score of 10 indicated pain as bad as you can imagine." (NCT00986258)
Timeframe: Baseline

Interventionunits on a scale (Mean)
Tapentadol Prolonged Release4.8

Change in Average Pain Intensity After 12 Weeks of Tapentadol Prolonged Release Treatment.

"For this pain assessment, the participant was to indicate the level of average pain experienced over the previous 3 days on an 11-point Numerical Rating Scale(NRS) where a score of 0 indicated no pain and a score of 10 indicated pain as bad as you can imagine. The value indicates the change from the baseline value on the 0 to 10 scale. A Negative value indicates a reduction in pain intensity from the baseline average pain intensity." (NCT00986258)
Timeframe: Baseline; End of Week 12 (12 weeks)

Interventionunits on a scale (Mean)
Tapentadol Prolonged Release-1.3

Change in Average Pain Intensity After 6 Weeks of Tapentadol Prolonged Release Treatment.

"For this pain assessment, the participant was to indicate the level of average pain experienced over the previous 3 days on an 11-point Numerical Rating Scale(NRS) where a score of 0 indicated no pain and a score of 10 indicated pain as bad as you can imagine. The value indicates the change from the baseline value on the 0 to 10 scale. A negative value indicates a reduction in pain intensity from the baseline average pain intensity." (NCT00986258)
Timeframe: Baseline; End of Week 6 (6 weeks)

Interventionunits on a scale (Mean)
Tapentadol Prolonged Release-0.9

Mean Equipotency Ratio of Tapentadol Compared to Buprenorphine

Tapentadol was compared to Buprenorphine with Buprenorphine set to 1. The average total daily dose of Tapentadol at which a pain score equivalent or below to the pain score at the end of observation period under Buprenorphine was reached was documented as the equipotent or equianalgesic dose to the total daily dose of the previously used Buprenorphine. (NCT00986258)
Timeframe: Baseline; End of Week 6 (6 Weeks)

InterventionRatio (Number)
Tapentadol210.0

Mean Equipotency Ratio of Tapentadol Compared to Fentanyl

Tapentadol was compared to Transdermal Fentanyl with Fentanyl set to 1. The average total daily dose of Tapentadol at which a pain score equivalent or below to the pain score at the end of observation period under Transdermal Fentanyl was reached was documented as the equipotent or equianalgesic dose to the total daily dose of the previously used Fentanyl. (NCT00986258)
Timeframe: Baseline; End of Week 6 (6 Weeks)

InterventionRatio (Number)
Tapentadol250.7

Mean Equipotency Ratio of Tapentadol Compared to Hydromorphone

Tapentadol was compared to Hydromorphone with Hydromorphone set to 1. The average total daily dose of Tapentadol at which a pain score equivalent or below to the pain score at the end of observation period under Hydromorphone was reached was documented as the equipotent or equianalgesic dose to the total daily dose of the previously used Hydromorphone. (NCT00986258)
Timeframe: Baseline; End of Week 6 (6 Weeks)

InterventionRatio (Number)
Tapentadol10.5

Mean Equipotency Ratio of Tapentadol Compared to Morphine

Tapentadol was compared to Morphine with Morphine set to 1. The average total daily dose of Tapentadol at which a pain score equivalent or below to the pain score at the end of observation period under Morphine was reached was documented as the equipotent or equianalgesic dose to the total daily dose of the previously used Morphine. (NCT00986258)
Timeframe: Baseline; End of Week 6 (6 Weeks)

InterventionRatio (Number)
Tapentadol3.0

Mean Equipotency Ratio of Tapentadol Compared to Oxycodone

Tapentadol was compared to Oxycodone with Oxycodone set to 1. The average total daily dose of Tapentadol at which a pain score equivalent or below to the pain score at the end of observation period under Oxycodone was reached was documented as the equipotent or equianalgesic dose to the total daily dose of the previously used Oxycodone. (NCT00986258)
Timeframe: Baseline; End of Week 6 (6 Weeks)

InterventionRatio (Number)
Tapentadol5.3

Number of Participants That Responded to Treatment

Participants were considered responders if they reported the same or less average pain intensity over a 3 day period (NRS-3) after 6 weeks of tapentadol prolonged release treatment compared to their previous analgesic treatment (over a 3 day period on the Numeric Rating Scale) at Week 6 compared with Week-1. (NCT00986258)
Timeframe: 6 weeks

Interventionparticipants (Number)
Tapentadol Prolonged Release76

painDETECT Assessment at Baseline

"The painDETECT questionnaire was used to determine the possibility of the presence of a neuropathic pain component. It is a participant completed questionnaire. A total score is calculated. Participants with a score between 0 and 12 are scored as being negative (no neuropathic pain component). Value between 19 and 38 as being positive (presence of neuropathic component). Values from 13 to 18 are scored as being unclear." (NCT00986258)
Timeframe: Baseline

Interventionunits on a scale (Mean)
Baseline painDETECT Negative Group6.5
Baseline painDETECT Unclear Group14.7
Baseline painDETECT Positive Group21.1

painDETECT Assessment for Participants After 12 Weeks of Tapentadol Prolonged Release Treatment

"The baseline painDETECT score was reassessed at the end of Week 12.~It is a participant completed questionnaire. A total score is calculated. Participants with a score between 0 and 12 are scored as being negative (no neuropathic pain component). Value between 19 and 38 as being positive (presence of neuropathic component). Values from 13 to 18 are scored as being unclear." (NCT00986258)
Timeframe: End of Week 12

Interventionunits on a scale (Mean)
Baseline painDETECT Negative Group6.8
Baseline painDETECT Unclear Group8.6
Baseline painDETECT Positive Group16.5

painDETECT Assessment for Participants After 6 Weeks of Tapentadol Prolonged Release Treatment

"The baseline painDETECT score was reassessed at the end of Week 6.~It is a participant completed questionnaire. A total score is calculated. Participants with a score between 0 and 12 are scored as being negative (no neuropathic pain component). Value between 19 and 38 as being positive (presence of neuropathic component). Values from 13 to 18 are scored as being unclear." (NCT00986258)
Timeframe: End of Week 6

Interventionunits on a scale (Mean)
Baseline painDETECT Negative Group7.5
Baseline painDETECT Unclear Group10.5
Baseline painDETECT Positive Group17.4

Change in the Health Survey Scores Form (SF-36)

The Scores Form 36 (SF-36) includes several brief questions on 8 aspects, (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional and mental health) that a participant was asked to score over the last week. A higher score indicates an improvement in health. All domains are scored on a scale from 0 (negative health) to 100 (positive health), with 100 representing the best possible health state. A positive mean value indicates an improvement from baseline. (NCT00986258)
Timeframe: Baseline; End of Week 12 (12 Weeks)

Interventionunits on a scale (Mean)
Physical FunctioningBodily PainGeneral HealthVitalitySocial FunctioningRole EmotionalMental HealthRole Physical
Tapentadol Prolonged Release10.514.15.712.011.713.99.810.7

Change in the Health Survey Scores Form (SF-36)

The Scores Form 36 (SF-36) includes several brief questions on 8 aspects, (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional and mental health) that a participant was asked to score over the last week. A higher score indicates an improvement in health. All domains are scored on a scale from 0 (negative health) to 100 (positive health), with 100 representing the best possible health state. A positive mean value indicates an improvement from baseline. (NCT00986258)
Timeframe: Baseline; End of Week 6 (6 Weeks)

Interventionunits on a scale (Mean)
Physical FunctioningBodily PainGeneral HealthVitalitySocial FunctioningRole EmotionalMental HealthRole Physical
Tapentadol Prolonged Release8.411.65.99.28.0-1.45.16.9

Neuropathic Pain Symptom Inventory (NPSI) Sub-scores and Overall Score

"All participants were requested to complete the NPSI (Neuropathic Pain Symptom Inventory) questionnaire at this visit. Each participant rated their own neuropathic pain symptoms by answering ten questions relating to neuropathic symptoms on an 11-point scale 0 (not present) to 10 (worst imaginable) for each question. The higher the score for a question (sub-scale) the more bothersome the symptom is for the participant.~Results are reported as the mean (average) for each neuropathic symptom in a sub-scale.~The mean score is reported on a scale of 0 (not present in the group) to 1 (symptom has the maximum imaginable intensity for the whole group)." (NCT00986258)
Timeframe: End of Week 12

Interventionunits on a scale (Mean)
Sub-score burning painSub-score pressing painSub-score paroxysmal painSub-score evoked painSub-score paresthesia / dysthesiaOverall score
Tapentadol Prolonged Release0.270.3020.2540.2730.2990.280

Neuropathic Pain Symptom Inventory (NPSI) Sub-scores and Overall Score

"All participants were requested to complete the NPSI (Neuropathic Pain Symptom Inventory) questionnaire at this visit. Each participant rated their own neuropathic pain symptoms by answering ten questions relating to neuropathic symptoms on an 11-point scale 0 (not present) to 10 (worst imaginable) for each question. The higher the score for a question (sub-scale) the more bothersome the symptom is for the participant.~Results are reported as the mean for each neuropathic symptom in a sub-scale. The mean score is reported on a scale of 0 (not present in the group) to 1 (symptom has the maximum imaginable intensity for the whole group)." (NCT00986258)
Timeframe: End of Week 6

Interventionunits on a scale (Mean)
Sub-score burning painSub-score pressing painSub-score paroxysmal painSub-score evoked painSub-score paresthesia / dysthesiaOverall score
Tapentadol Prolonged Release0.320.3220.2710.2740.3020.297

Neuropathic Pain Symptom Inventory (NPSI) Sub-scores and Overall Score

"All participants were requested to complete the NPSI (Neuropathic Pain Symptom Inventory) questionnaire at this visit. Each participant rated their own neuropathic pain symptoms by answering ten questions relating to neuropathic symptoms on an 11-point scale 0 (not present) to 10 (worst imaginable) for each question. The higher the score for a question (sub-scale) the more bothersome the symptom is for the participant.~Results are reported as the mean for each neuropathic symptom in the sub-scale. The mean score is reported on a scale of 0 (not present in the group) to 1 (symptom has the maximum imaginable intensity for the whole group)." (NCT00986258)
Timeframe: Baseline

Interventionunits on a scale (Mean)
Sub-score burning painSub-score pressing painSub-score paroxysmal painSub-score evoked painSub-score paresthesia / dysthesiaOverall score
Tapentadol Prolonged Release0.410.4050.4220.3850.4240.408

Patient Global Impression of Change

In the Patient Global Impression of Change (PGIC) the participant indicates the perceived change over the treatment period. The participant is requested to choose one of seven categories. Scores range from very much improved to very much worse. (NCT00986258)
Timeframe: Baseline; End of Week 12 (12 Weeks)

Interventionparticipants (Number)
Very much improvedMuch improvedMinimally improvedNo changeMinimally worseMuch worseVery much worse
Tapentadol Prolonged Release934389210

Patient Global Impression of Change

In the Patient Global Impression of Change (PGIC) the participant indicates the perceived change over the treatment period. The participant is requested to choose one of seven categories. Scores range from very much improved to very much worse. (NCT00986258)
Timeframe: Baseline; End of Week 6 (6 Weeks)

Interventionparticipants (Number)
Very much improvedMuch improvedMinimally improvedNo changeMinimally worseMuch worseVery much worse
Tapentadol Prolonged Release5294711630

NRS Pain Score After Blunt Dissection

Patient reported NRS pain scores after Blunt Dissection. The NRS for pain is a reliable and validated measure of pain intensity ranging from 0 - no pain, to 10 - worst pain imaginable. (NCT03872700)
Timeframe: Measured once anytime up to 60 minutes following intranasal administration

Interventionscore on a scale (Mean)
Intranasal Fentanyl4.1
Placebo4.4

NRS Pain Score After Irrigation

Patient reported NRS pain scores after Irrigation. The NRS for pain is a reliable and validated measure of pain intensity ranging from 0 - no pain, to 10 - worst pain imaginable. (NCT03872700)
Timeframe: Measured once anytime up to 60 minutes following intranasal administration

Interventionscore on a scale (Mean)
Intranasal Fentanyl3.4
Placebo2.6

NRS Pain Score After Lidocaine Injection

Patient reported NRS pain scores after Lidocaine injection. The NRS for pain is a reliable and validated measure of pain intensity ranging from 0 - no pain, to 10 - worst pain imaginable. (NCT03872700)
Timeframe: Following Lidocaine injection measured once anytime up to 12 minutes after intranasal administration

Interventionscore on a scale (Mean)
Intranasal Fentanyl8.4
Placebo8.0

NRS Pain Score After Packing of Abscess

Patient reported pain after Packing of abscess. The NRS for pain is a reliable and validated measure of pain intensity ranging from 0 - no pain, to 10 - worst pain imaginable. (NCT03872700)
Timeframe: Measured once at the time of completion of application of the bandage, up to 60 minutes following intranasal administration

Interventionscore on a scale (Mean)
Intranasal Fentanyl4.5
Placebo3.9

NRS Pain Score Following Incision

Patient reported NRS pain scores following Incision. The NRS for pain is a reliable and validated measure of pain intensity ranging from 0 - no pain, to 10 - worst pain imaginable. (NCT03872700)
Timeframe: Measured once anytime up to 60 minutes following intranasal administration

Interventionscore on a scale (Mean)
Intranasal Fentanyl3.9
Placebo3.9

Numerical Rating Scale (NRS) Pain Score at Baseline

Patient reported pain scores at baseline. The NRS for pain is a reliable and validated measure of pain intensity ranging from 0 - no pain, to 10 - worst pain imaginable. (NCT03872700)
Timeframe: Baseline

Interventionscore on a scale (Mean)
Intranasal Fentanyl8.3
Placebo8.1

Numerical Rating Scale (NRS) Pain Score for Overall Procedure

Patient reported pain scores for overall Procedure assessed immediately after placement of dressing at the end of procedure. The NRS for pain is a reliable and validated measure of pain intensity ranging from 0 - no pain, to 10 - worst pain imaginable. (NCT03872700)
Timeframe: Measured once following placement of dressing at completion of procedure, up to 60 minutes following intranasal administration

Interventionscore on a scale (Mean)
Intranasal Fentanyl6.2
Placebo7.0

Reviews

3 reviews available for fentanyl and Neuralgia

ArticleYear
Fentanyl-related compounds and derivatives: current status and future prospects for pharmaceutical applications.
    Future medicinal chemistry, 2014, Volume: 6, Issue:4

    Topics: Analgesics, Opioid; Animals; Fentanyl; Humans; Neuralgia; Receptors, Opioid, delta; Receptors, Opioi

2014
Fentanyl for neuropathic pain in adults.
    The Cochrane database of systematic reviews, 2016, Oct-11, Volume: 10

    Topics: Aged; Analgesics, Opioid; Female; Fentanyl; Humans; Male; Neuralgia; Pain Measurement; Randomized Co

2016
Intranasal fentanyl: from pharmacokinetics and bioavailability to current treatment applications.
    Expert review of anticancer therapy, 2010, Volume: 10, Issue:7

    Topics: Administration, Cutaneous; Administration, Intranasal; Administration, Oral; Adult; Aged; Biological

2010
Intranasal fentanyl: from pharmacokinetics and bioavailability to current treatment applications.
    Expert review of anticancer therapy, 2010, Volume: 10, Issue:7

    Topics: Administration, Cutaneous; Administration, Intranasal; Administration, Oral; Adult; Aged; Biological

2010
Intranasal fentanyl: from pharmacokinetics and bioavailability to current treatment applications.
    Expert review of anticancer therapy, 2010, Volume: 10, Issue:7

    Topics: Administration, Cutaneous; Administration, Intranasal; Administration, Oral; Adult; Aged; Biological

2010
Intranasal fentanyl: from pharmacokinetics and bioavailability to current treatment applications.
    Expert review of anticancer therapy, 2010, Volume: 10, Issue:7

    Topics: Administration, Cutaneous; Administration, Intranasal; Administration, Oral; Adult; Aged; Biological

2010

Trials

7 trials available for fentanyl and Neuralgia

ArticleYear
Gabapentin versus Transdermal Fentanyl Matrix for the Alleviation of Chronic Neuropathic Pain of Radicular Origin: A Randomized Blind Multicentered Parallel-Group Noninferiority Trial.
    Pain research & management, 2019, Volume: 2019

    Topics: Administration, Cutaneous; Adult; Analgesics; Double-Blind Method; Female; Fentanyl; Gabapentin; Hum

2019
Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study.
    Advances in therapy, 2013, Volume: 30, Issue:3

    Topics: Adult; Aged; Analgesics, Opioid; Buprenorphine; Chronic Pain; Constipation; Delayed-Action Preparati

2013
Efficacy and safety of sublingual fentanyl tablets for the management of breakthrough pain in patients with chronic musculoskeletal pain with neuropathic component: multicenter prospective study.
    Clinical drug investigation, 2015, Volume: 35, Issue:3

    Topics: Administration, Sublingual; Adult; Aged; Aged, 80 and over; Breakthrough Pain; Drug-Related Side Eff

2015
Methadone is superior to fentanyl in treating neuropathic pain in patients with head-and-neck cancer.
    European journal of cancer (Oxford, England : 1990), 2016, Volume: 65

    Topics: Adult; Aged; Analgesics, Opioid; Cancer Pain; Female; Fentanyl; Head and Neck Neoplasms; Humans; Mal

2016
Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
    Clinical therapeutics, 2007, Volume: 29, Issue:4

    Topics: Administration, Buccal; Aged; Aged, 80 and over; Analgesics, Opioid; Chronic Disease; Double-Blind M

2007
Prolonged treatment with transdermal fentanyl in neuropathic pain.
    Journal of pain and symptom management, 1998, Volume: 16, Issue:4

    Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Opioid; Double-Blind Method; Female; Fentanyl; H

1998
A comparison of minidose lidocaine-fentanyl and conventional-dose lidocaine spinal anesthesia.
    Anesthesia and analgesia, 2000, Volume: 91, Issue:4

    Topics: Adjuvants, Anesthesia; Adult; Anesthesia Recovery Period; Anesthesia, Spinal; Anesthetics, Local; Ar

2000

Other Studies

25 other studies available for fentanyl and Neuralgia

ArticleYear
Piperidine propionamide as a scaffold for potent sigma-1 receptor antagonists and mu opioid receptor agonists for treating neuropathic pain.
    European journal of medicinal chemistry, 2020, Apr-01, Volume: 191

    Topics: Amides; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Formaldehyde; Guinea Pigs

2020
Optimization of bifunctional piperidinamide derivatives as σ
    European journal of medicinal chemistry, 2021, Dec-15, Volume: 226

    Topics: Acetic Acid; Amides; Animals; Behavior, Animal; Dose-Response Relationship, Drug; Formaldehyde; Guin

2021
Tapentadol in Cancer Patients with Neuropathic Pain: A Comparison of Methadone, Oxycodone, Fentanyl, and Hydromorphone.
    Biological & pharmaceutical bulletin, 2021, Volume: 44, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Cancer Pain; Dose-Response Relationship, Drug; F

2021
Accessibility of axonal G protein coupled mu-opioid receptors requires conceptual changes of axonal membrane targeting for pain modulation.
    Journal of controlled release : official journal of the Controlled Release Society, 2017, Dec-28, Volume: 268

    Topics: Analgesics, Opioid; Animals; Axons; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Fentanyl; Freund's Adjuvant

2017
The Association between Patient Characteristics and Opioid Treatment Response in Neuropathic and Nociceptive Pain due to Cancer.
    Journal of palliative medicine, 2019, Volume: 22, Issue:2

    Topics: Aged; Analgesics, Opioid; Cancer Pain; Female; Fentanyl; Head and Neck Neoplasms; Humans; Male; Midd

2019
Opioid responsiveness of nociceptive versus mixed pain in clinical cancer patients.
    European journal of cancer (Oxford, England : 1990), 2018, Volume: 105

    Topics: Aged; Analgesics; Analgesics, Opioid; Cancer Pain; Drug Therapy, Combination; Female; Fentanyl; Huma

2018
Oxycodone, fentanyl, and morphine amplify established neuropathic pain in male rats.
    Pain, 2019, Volume: 160, Issue:11

    Topics: Analgesics, Opioid; Animals; Chronic Pain; Disease Models, Animal; Fentanyl; Male; Morphine; Neuralg

2019
Safety and efficacy of transdermal buprenorphine and transdermal fentanyl in the treatment of neuropathic pain in AIDS patients.
    Minerva anestesiologica, 2013, Volume: 79, Issue:8

    Topics: Acquired Immunodeficiency Syndrome; Adult; Analgesics, Opioid; Buprenorphine; CD4-CD8 Ratio; Female;

2013
Current developments in the treatment of neuropathic pain in AIDS patients.
    Minerva anestesiologica, 2013, Volume: 79, Issue:8

    Topics: Acquired Immunodeficiency Syndrome; Analgesics, Opioid; Buprenorphine; Female; Fentanyl; Humans; Mal

2013
Morphine and oxycodone, but not fentanyl, exhibit antinociceptive effects mediated by G-protein inwardly rectifying potassium (GIRK) channels in an oxaliplatin-induced neuropathy rat model.
    Neuroscience letters, 2014, Sep-19, Volume: 580

    Topics: Analgesics, Opioid; Animals; Antineoplastic Agents; Fentanyl; G Protein-Coupled Inwardly-Rectifying

2014
Establishment of opioid-induced rewarding effects under oxaliplatin- and Paclitaxel-induced neuropathy in rats.
    Journal of pharmacological sciences, 2014, Volume: 126, Issue:1

    Topics: Analgesics, Opioid; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Fentanyl; Mal

2014
Successful use of pregabalin by the rectal route to treat chronic neuropathic pain in a patient with complete intestinal failure.
    BMJ case reports, 2015, Oct-29, Volume: 2015

    Topics: Administration, Rectal; Aged; Analgesics; Analgesics, Opioid; Cannabinoids; Fentanyl; Humans; Intest

2015
Successful Management of Corneal Neuropathic Pain with Intrathecal Targeted Drug Delivery.
    Pain medicine (Malden, Mass.), 2016, Volume: 17, Issue:7

    Topics: Adult; Analgesics; Bupivacaine; Cervical Vertebrae; Cornea; Female; Fentanyl; Humans; Infusion Pumps

2016
Letter response: Methadone is superior to fentanyl in treating neuropathic pain in patients with head-and-neck cancer.
    European journal of cancer (Oxford, England : 1990), 2016, Volume: 68

    Topics: Analgesics, Opioid; Fentanyl; Head and Neck Neoplasms; Humans; Methadone; Neuralgia; Pain; Pain Meas

2016
Methadone is superior to fentanyl in treating neuropathic pain in patients with head-and-neck cancer.
    European journal of cancer (Oxford, England : 1990), 2016, Volume: 68

    Topics: Analgesics, Opioid; Fentanyl; Head and Neck Neoplasms; Humans; Methadone; Neoplasms; Neuralgia; Pain

2016
Case report. Intravenous fentanyl patient-controlled analgesia for perioperative treatment of neuropathic/ischaemic pain in haemodialysis patients: a case series.
    Journal of clinical pharmacy and therapeutics, 2010, Volume: 35, Issue:5

    Topics: Adult; Aged; Analgesia, Patient-Controlled; Analgesics, Opioid; Diabetic Neuropathies; Female; Fenta

2010
Possible involvement of prolonging spinal µ-opioid receptor desensitization in the development of antihyperalgesic tolerance to µ-opioids under a neuropathic pain-like state.
    Addiction biology, 2013, Volume: 18, Issue:4

    Topics: Analgesics, Opioid; Animals; beta-Endorphin; Dose-Response Relationship, Drug; Drug Tolerance; Femal

2013
[Oxycodone and pregabalin using transdermal fentanyl patch provided relief of symptoms for postherpetic neuropathic pain in a patient with non-small cell lung cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:10

    Topics: Aged; Analgesics, Opioid; Carcinoma, Non-Small-Cell Lung; Fentanyl; gamma-Aminobutyric Acid; Humans;

2011
A successful switch from transdermal fentanyl to transdermal buprenorphine in a patient with neuropathic pain: a case report.
    The American journal of hospice & palliative care, 2014, Volume: 31, Issue:1

    Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Buprenorphine; Drug Substitution; Female; Fent

2014
Nerve-stimulator-guided repeated pudendal nerve block for treatment of pudendal neuralgia.
    European journal of anaesthesiology, 2006, Volume: 23, Issue:5

    Topics: Analgesics; Analgesics, Opioid; Anesthetics, Local; Bupivacaine; Clonidine; Electric Stimulation; Ep

2006
Opioid self-administration in the nerve-injured rat: relevance of antiallodynic effects to drug consumption and effects of intrathecal analgesics.
    Anesthesiology, 2007, Volume: 106, Issue:2

    Topics: Adenosine; Analgesics, Opioid; Animals; Clonidine; Dose-Response Relationship, Drug; Fentanyl; Heroi

2007
[Transdermal fentanyl for neuropathic pain: a case report].
    Agri : Agri (Algoloji) Dernegi'nin Yayin organidir = The journal of the Turkish Society of Algology, 2006, Volume: 18, Issue:4

    Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Female; Fentanyl; Humans; Neuralgia; Pain, Int

2006
Inefficacy of high-dose transdermal fentanyl in a patient with neuropathic pain, a case report.
    European journal of pain (London, England), 2001, Volume: 5, Issue:3

    Topics: Administration, Cutaneous; Analgesia, Epidural; Analgesics, Opioid; Anesthetics, Local; Breast Neopl

2001
Neuralgia following lumbar sympathectomy.
    Annals of vascular surgery, 1988, Volume: 2, Issue:3

    Topics: Drug Therapy, Combination; Fentanyl; Humans; Injections, Epidural; Lumbosacral Region; Methylprednis

1988
Effect of stellate ganglion block with fentanyl on postherpetic neuralgia with a sympathetic component.
    Anesthesia and analgesia, 1988, Volume: 67, Issue:9

    Topics: Female; Fentanyl; Herpes Zoster; Humans; Middle Aged; Nerve Block; Neuralgia; Stellate Ganglion; Sym

1988